Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (SE:IMMNOV)
:IMMNOV
IMMNOV Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.24 - kr1.05
Previous CloseN/A
Volume868.16K
Average Volume (3M)12.46M
Market Cap
$145.08M
Enterprise Valuekr93.16M
Total Cash (Recent Filing)$29.27M
Total Debt (Recent Filing)$467.00K
Price to Earnings (P/E)―
Beta-0.90
Next Earnings
Nov 19, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding306,083,070
10 Day Avg. Volume7,558,644
30 Day Avg. Volume12,458,616
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue101.37
Enterprise Value/Gross Profit-3.15
Enterprise Value/Ebitda-1.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.24 and its highest was kr1.05 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is $145.08M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 19, 2025 which is in 49 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 28, 2025. The company reported -kr0.14 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.14.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.06.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 306,083,070 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -26.444%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMNOV Company Deck
IMMNOV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in test development and financial management, with successful analytical validation and a promising rights issue. However, challenges remain with increased cash burn, limited initial revenue, and regulatory hurdles. The company is optimistic about its strategic plans for 2025, particularly the U.S. launch.View all SE:IMMNOV earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―
Options Prices
Currently, No data available
---